vs
Side-by-side financial comparison of PROCORE TECHNOLOGIES, INC. (PCOR) and Bio-Techne (TECH). Click either name above to swap in a different company.
PROCORE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($349.1M vs $295.9M, roughly 1.2× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -10.8%, a 23.6% gap on every dollar of revenue. On growth, PROCORE TECHNOLOGIES, INC. posted the faster year-over-year revenue change (15.6% vs -6.4%). Over the past eight quarters, PROCORE TECHNOLOGIES, INC.'s revenue compounded faster (13.8% CAGR vs 4.2%).
Procore Technologies is an American construction management software as a service company founded in 2002, with headquarters in Carpinteria, California. Procore hosts a platform to connect those involved in the construction industry on a global platform. The software allows for the creation of simplified workflows and displays a consolidated view of construction products that includes the tracking of tasks, management of project workflows, and scheduling.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
PCOR vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $349.1M | $295.9M |
| Net Profit | $-37.6M | $38.0M |
| Gross Margin | 80.1% | 64.6% |
| Operating Margin | -12.3% | 18.4% |
| Net Margin | -10.8% | 12.8% |
| Revenue YoY | 15.6% | -6.4% |
| Net Profit YoY | 39.6% | 68.3% |
| EPS (diluted) | $-0.25 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $349.1M | $295.9M | ||
| Q3 25 | $338.9M | — | ||
| Q2 25 | $323.9M | $317.0M | ||
| Q1 25 | $310.6M | $316.2M | ||
| Q4 24 | $302.0M | $297.0M | ||
| Q3 24 | $295.9M | $289.5M | ||
| Q2 24 | $284.3M | $306.1M | ||
| Q1 24 | $269.4M | $303.4M |
| Q4 25 | $-37.6M | $38.0M | ||
| Q3 25 | $-9.1M | — | ||
| Q2 25 | $-21.1M | $-17.7M | ||
| Q1 25 | $-33.0M | $22.6M | ||
| Q4 24 | $-62.3M | $34.9M | ||
| Q3 24 | $-26.4M | $33.6M | ||
| Q2 24 | $-6.3M | $40.6M | ||
| Q1 24 | $-11.0M | $49.1M |
| Q4 25 | 80.1% | 64.6% | ||
| Q3 25 | 79.7% | — | ||
| Q2 25 | 79.1% | 62.7% | ||
| Q1 25 | 79.1% | 67.9% | ||
| Q4 24 | 81.2% | 65.3% | ||
| Q3 24 | 81.4% | 63.2% | ||
| Q2 24 | 83.1% | 66.4% | ||
| Q1 24 | 83.0% | 67.4% |
| Q4 25 | -12.3% | 18.4% | ||
| Q3 25 | -4.4% | — | ||
| Q2 25 | -9.3% | -7.5% | ||
| Q1 25 | -11.7% | 12.2% | ||
| Q4 24 | -21.9% | 16.0% | ||
| Q3 24 | -12.3% | 13.8% | ||
| Q2 24 | -5.2% | 15.0% | ||
| Q1 24 | -7.0% | 22.1% |
| Q4 25 | -10.8% | 12.8% | ||
| Q3 25 | -2.7% | — | ||
| Q2 25 | -6.5% | -5.6% | ||
| Q1 25 | -10.6% | 7.1% | ||
| Q4 24 | -20.6% | 11.7% | ||
| Q3 24 | -8.9% | 11.6% | ||
| Q2 24 | -2.2% | 13.3% | ||
| Q1 24 | -4.1% | 16.2% |
| Q4 25 | $-0.25 | $0.24 | ||
| Q3 25 | $-0.06 | — | ||
| Q2 25 | $-0.14 | $-0.11 | ||
| Q1 25 | $-0.22 | $0.14 | ||
| Q4 24 | $-0.42 | $0.22 | ||
| Q3 24 | $-0.18 | $0.21 | ||
| Q2 24 | $-0.04 | $0.26 | ||
| Q1 24 | $-0.08 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $768.5M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $1.3B | $2.0B |
| Total Assets | $2.2B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $768.5M | $172.9M | ||
| Q3 25 | $684.0M | — | ||
| Q2 25 | $620.9M | $162.2M | ||
| Q1 25 | $566.7M | $140.7M | ||
| Q4 24 | $775.4M | $177.5M | ||
| Q3 24 | $756.9M | $187.5M | ||
| Q2 24 | $735.4M | $152.9M | ||
| Q1 24 | $744.6M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $1.3B | $2.0B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | $1.9B | ||
| Q1 25 | $1.2B | $2.0B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $1.3B | $2.1B | ||
| Q2 24 | $1.3B | $2.1B | ||
| Q1 24 | $1.2B | $2.0B |
| Q4 25 | $2.2B | $2.5B | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.0B | $2.6B | ||
| Q1 25 | $1.9B | $2.6B | ||
| Q4 24 | $2.1B | $2.7B | ||
| Q3 24 | $2.0B | $2.7B | ||
| Q2 24 | $2.0B | $2.7B | ||
| Q1 24 | $1.9B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $114.9M | — |
| Free Cash FlowOCF − Capex | $109.2M | — |
| FCF MarginFCF / Revenue | 31.3% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $282.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $114.9M | — | ||
| Q3 25 | $88.5M | — | ||
| Q2 25 | $30.8M | $98.2M | ||
| Q1 25 | $66.0M | $41.1M | ||
| Q4 24 | $29.1M | $84.3M | ||
| Q3 24 | $39.3M | $63.9M | ||
| Q2 24 | $58.7M | $75.5M | ||
| Q1 24 | $69.1M | $81.0M |
| Q4 25 | $109.2M | — | ||
| Q3 25 | $83.1M | — | ||
| Q2 25 | $27.9M | $93.3M | ||
| Q1 25 | $62.0M | $31.0M | ||
| Q4 24 | $17.4M | $77.5M | ||
| Q3 24 | $35.7M | $54.7M | ||
| Q2 24 | $56.8M | $57.5M | ||
| Q1 24 | $67.1M | $64.5M |
| Q4 25 | 31.3% | — | ||
| Q3 25 | 24.5% | — | ||
| Q2 25 | 8.6% | 29.4% | ||
| Q1 25 | 20.0% | 9.8% | ||
| Q4 24 | 5.8% | 26.1% | ||
| Q3 24 | 12.1% | 18.9% | ||
| Q2 24 | 20.0% | 18.8% | ||
| Q1 24 | 24.9% | 21.3% |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 1.3% | 3.2% | ||
| Q4 24 | 3.9% | 2.3% | ||
| Q3 24 | 1.2% | 3.2% | ||
| Q2 24 | 0.7% | 5.9% | ||
| Q1 24 | 0.8% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
